Form D · Biotechnology

BioGene Therapeutics Inc.

Austin, TX · CIK 0002140719

Offering snapshot reported Aug 7, 2026 · SEC filing

Reported sold
$3M
Offering amount: $3M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jun 5, 2026
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 7, 2026Initial$3,000,000No comparison1SEC filing
Aug 6, 2026Initial$250,000No comparison1SEC filing
Aug 6, 2026Initial$250,000No comparison1SEC filing
Aug 6, 2026Initial$3,000,000No comparison1SEC filing
Jul 23, 2026Initial$4,550,000No comparison6SEC filing

Offering details

Securities
Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-593463
Consists of the grant of 100,000 stock options and 500,000 restricted share units and the underlying shares.

Source: Form D, filed Aug 7, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Steve Glover Director
David Tyronne Howton Director
Patroski Lawson Director
Raj Pruthi Director
Deepak Sampath Director
Stephen Van Deventer Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
5900 Balcones Dr, Ste 100
Austin, TX, 78731
Phone: 1-512-379-7526